LEIDOS BIOMEDICAL RESEARCH INC - ELABORATION AND USE OF SYNGENIC PRE-CLINICAL MODELS FOR CANCER DRUG DEVELOPMENT

PIID: 75N91021F00017

Signed Date: Sep 16, 2021Effective Date: Sep 16, 2021End Date: Closes in 1075 days

Award $

$21.7M

Vendor

LEIDOS BIOMEDICAL RESEARCH INC

NAICS

541715

Signed Date

Sep 16, 2021

Key Details

Dollars Obligated

$21.7M

Base & All Options

$21.7M

Awarding Agency

Awarding Sub-Agency

National Institutes of Health

NAICS Code

Parent IDIQ (PIID)

75N91019D00024

Product Service Code

AN12 - HEALTH R&D SERVICES; HEALTH CARE SERVICES; APPLIED RESEARCH

Extent Competed

FULL AND OPEN COMPETITION

Place of Performance

FREDERICK, MD

ELABORATION AND USE OF SYNGENIC PRE-CLINICAL MODELS FOR CANCER DRUG DEVELOPMENT

On Sep 16, 2021, Department of Health and Human Services obligated $21,659,701.83 to LEIDOS BIOMEDICAL RESEARCH INC for elaboration and use of syngenic pre-clinical models for cancer drug development. The award is classified under NAICS 541715 — RESEARCH AND DEVELOPMENT IN THE PHYSICAL, ENGINEERING, AND LIFE SCIENCES (EXCEPT NANOTECHNOLOGY AND BIOTECHNOLOGY). Competition extent: full and open competition. Performance is located in FREDERICK, MD. The contract is scheduled through Aug 21, 2029. This award is one of several similar procurements from Department of Health and Human Services under NAICS 541715 — related awards are listed below.